Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

Higher yields, greater resilience to climatic changes or diseases—the demands on crop plants are constantly growing. To ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...